Clarithromycin-Resistant H pylori Faces New Foe
Abstract
News & Analysis News From the Food and Drug Administration Clarithromycin-Resistant H pylori sis, the first triple-combination therapy that tion, sweat chloride concentration, and re- Faces New Foe treats the underlying cause of most pa- spiratory quality of life compared with the The FDA has approved a combination drug tients’ disease has received FDA approval. tezacaftor-ivacaftor group. for Helicobacter pylori infection that’s Marketed as Trikafta, the drug com- Serious...